An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?

As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xu, Li, Huiping, Coussy, Florence, Callens, Celine, Lerebours, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736652/
https://www.ncbi.nlm.nih.gov/pubmed/31564802
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.04.03

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736652/
https://www.ncbi.nlm.nih.gov/pubmed/31564802
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.04.03

Ejemplares similares